Anzeige
Mehr »
Samstag, 13.09.2025 - Börsentäglich über 12.000 News
Investment Idee: Einsteigen bevor sich die Schleuse öffnet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
06.08.Bayer's layoff count now at 12,000-plus as its fortunes begin to turn
06.08.BeOne, now a Swiss company, widens Brukinsa's BTK lead over AstraZeneca's Calquence
06.08.Supreme Group buys Pivot Design, bringing agency takeover tally to 9 in 18 months
05.08.Trump ups the ante on pharma tariffs, saying they will reach 250%
05.08.BioNTech cuts 90 more US jobs as the drugmaker hones pipeline focus
05.08.TV drug ad spending plummeted in July, while AbbVie's Skyrizi regained the lead
05.08.Currax cranks up Contrave campaigns, taking obesity ad national and telling patients' stories
05.08.Pfizer CEO touts 'extremely productive' talks with Trump administration as MFN pricing, tariff threats close in
05.08.BioMarin touts promising early result for potential Voxzogo successor
05.08.Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain
05.08.Y-mAbs signs off on $412M sale to SERB Pharmaceuticals, sending shares up 100%
05.08.Novo Nordisk faces investor lawsuit over 'false and misleading' semaglutide sales projections
04.08.AbbVie flashes eye-opening results for Rinvoq in alopecia areata
04.08.Incyte's new CEO pledges 'fresh look' at business, outlines dealmaking strategy
04.08.Lilly confirms plan to sell NJ plant amid larger US production ramp-up
02.08.Regulatory tracker: AstraZeneca's Imfinzi stomach cancer expansion bid snags FDA priority review
01.08.Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions
01.08.Lenz's Vizz wins FDA approval to crack 'large, untapped' market for presbyopia
01.08.Despite ongoing decline, Moderna's Spikevax sales beat expectations in Q2
01.08.J&J coins the term '3rd opinion,' debuts awareness campaign to empower lung cancer patients
01.08.Merz Aesthetics gives sales and marketing leadership a face-lift
01.08.Alnylam exceeds $50B market cap as Amvuttra heart disease launch wows Wall Street
31.07.White House threatens to 'deploy every tool in our arsenal' to implement most-favored-nation drug pricing
31.07.Merck will lay off 6,000, reducing workforce by 8% in cost-cutting purge
31.07.Sanofi touts tariff resilience for rest of 2025 as CEO admits many unknowns persist